PROKIDNEY CORP (PROK) Stock Price, Quote, News and Overview
NASDAQ:PROK - Nasdaq - KYG7S53R1049 - Common Stock - Currency: USD
PROK Quote, Performance and Key Statistics
3.29
+0.03 (+0.92%)
The current stock price of PROK is 3.29 USD. In the past month the price increased by 355.11%. In the past year, price increased by 34.29%.
PROK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.53 | 336.11B | ||
| AMGN | AMGEN INC | 14.77 | 164.85B | ||
| GILD | GILEAD SCIENCES INC | 15.01 | 144.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.61B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.71 | 60.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.87B | ||
| ARGX | ARGENX SE - ADR | 103.13 | 36.23B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.44 | 31.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.72B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.29B | ||
| INSM | INSMED INC | N/A | 19.72B | ||
| BIIB | BIOGEN INC | 8.31 | 19.27B |
Related stock screener links
About PROK
Company Profile
ProKidney Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. ProKidney Corp. is a clinical-stage cellular therapeutics company. The firm is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. The company is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.
Company Info
PROKIDNEY CORP
2000 Frontis Plaza Blvd., Suite 250
Winston-Salem NORTH CAROLINA US
Employees: 204
Phone: 13369997028
PROKIDNEY CORP / PROK FAQ
What is the stock price of PROKIDNEY CORP today?
The current stock price of PROK is 3.29 USD. The price increased by 0.92% in the last trading session.
What is the ticker symbol for PROKIDNEY CORP stock?
The exchange symbol of PROKIDNEY CORP is PROK and it is listed on the Nasdaq exchange.
On which exchange is PROK stock listed?
PROK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROKIDNEY CORP stock?
12 analysts have analysed PROK and the average price target is 5.71 USD. This implies a price increase of 73.62% is expected in the next year compared to the current price of 3.29. Check the PROKIDNEY CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROKIDNEY CORP worth?
PROKIDNEY CORP (PROK) has a market capitalization of 962.98M USD. This makes PROK a Small Cap stock.
How many employees does PROKIDNEY CORP have?
PROKIDNEY CORP (PROK) currently has 204 employees.
What are the support and resistance levels for PROKIDNEY CORP (PROK) stock?
PROKIDNEY CORP (PROK) has a support level at 3.04 and a resistance level at 3.3. Check the full technical report for a detailed analysis of PROK support and resistance levels.
Should I buy PROKIDNEY CORP (PROK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PROK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PROK, evaluating the profitability, health, valuation and growth aspects
- PROKIDNEY CORP (PROK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROKIDNEY CORP (PROK) Sales and EPS estimates to see what analysts future expectations are.
- PROKIDNEY CORP (PROK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROKIDNEY CORP (PROK) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROKIDNEY CORP (PROK) Stock Chart to make your own analysis
- PROKIDNEY CORP (PROK) Latest news and press-releases to stay up to date.
Does PROKIDNEY CORP (PROK) stock pay dividends?
PROK does not pay a dividend.
What is the Price/Earnings (PE) ratio of PROKIDNEY CORP (PROK)?
PROKIDNEY CORP (PROK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.6).
What is the Short Interest ratio of PROKIDNEY CORP (PROK) stock?
The outstanding short interest for PROKIDNEY CORP (PROK) is 15.5% of its float. Check the ownership tab for more information on the PROK short interest.
PROK Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PROK. When comparing the yearly performance of all stocks, PROK is one of the better performing stocks in the market, outperforming 97.63% of all stocks.
PROK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PROK. While PROK seems to be doing ok healthwise, there are quite some concerns on its profitability.
PROK Financial Highlights
Over the last trailing twelve months PROK reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -5.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.85% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PROK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to PROK. The Buy consensus is the average rating of analysts ratings from 12 analysts.